Dupilumab for the Treatment of Prurigo Nodularis
Skin Therapy Lett. 2023 Nov;28(6):7-9.ABSTRACTPrurigo nodularis (PN) is a chronic inflammatory skin condition characterized by the presence of pruritic nodules. Dupilumab was approved by the US Food and Drug Administration in September 2022 and Health Canada in July 2023 for the treatment of PN. Dupilumab is a human monoclonal immunoglobulin G4 antibody that binds the interleukin (IL)-4 receptor alpha subunit, blocking intercellular signalling of IL-4 and IL-13. Inhibition of these cytokines downregulates the inflammatory response and improves disease severity and pruritus. Two randomized controlled trials have shown dupil...
Source: Skin Therapy Letter - November 28, 2023 Category: Dermatology Authors: Ayaa Alkhaleefa Taylor Evart Woo Laurie Parsons Source Type: research
Risankizumab in Adults with Psoriatic Arthritis
Skin Therapy Lett. 2023 Nov;28(6):1-6.ABSTRACTPsoriatic arthritis (PsA) is a chronic inflammatory musculoskeletal disease associated with psoriasis. Its major clinical domains include peripheral and axial arthritis, enthesitis, dactylitis and skin and nail involvement. Approximately 30% of patients with psoriasis develop psoriatic arthritis. The pathophysiology of PsA is complex and involves a dysregulated immune response. In particular, interleukin (IL)-23 is a major regulatory cytokine that has been implicated in PsA, including bone remodeling, enthesitis, synovitis and psoriatic lesions. Risankizumab is a humanized immu...
Source: Skin Therapy Letter - November 28, 2023 Category: Dermatology Authors: Karla Machlab Jensen Yeung Melinda Gooderham Source Type: research
Dupilumab for the Treatment of Prurigo Nodularis
Skin Therapy Lett. 2023 Nov;28(6):7-9.ABSTRACTPrurigo nodularis (PN) is a chronic inflammatory skin condition characterized by the presence of pruritic nodules. Dupilumab was approved by the US Food and Drug Administration in September 2022 and Health Canada in July 2023 for the treatment of PN. Dupilumab is a human monoclonal immunoglobulin G4 antibody that binds the interleukin (IL)-4 receptor alpha subunit, blocking intercellular signalling of IL-4 and IL-13. Inhibition of these cytokines downregulates the inflammatory response and improves disease severity and pruritus. Two randomized controlled trials have shown dupil...
Source: Skin Therapy Letter - November 28, 2023 Category: Dermatology Authors: Ayaa Alkhaleefa Taylor Evart Woo Laurie Parsons Source Type: research
Risankizumab in Adults with Psoriatic Arthritis
Skin Therapy Lett. 2023 Nov;28(6):1-6.ABSTRACTPsoriatic arthritis (PsA) is a chronic inflammatory musculoskeletal disease associated with psoriasis. Its major clinical domains include peripheral and axial arthritis, enthesitis, dactylitis and skin and nail involvement. Approximately 30% of patients with psoriasis develop psoriatic arthritis. The pathophysiology of PsA is complex and involves a dysregulated immune response. In particular, interleukin (IL)-23 is a major regulatory cytokine that has been implicated in PsA, including bone remodeling, enthesitis, synovitis and psoriatic lesions. Risankizumab is a humanized immu...
Source: Skin Therapy Letter - November 28, 2023 Category: Dermatology Authors: Karla Machlab Jensen Yeung Melinda Gooderham Source Type: research
Dupilumab for the Treatment of Prurigo Nodularis
Skin Therapy Lett. 2023 Nov;28(6):7-9.ABSTRACTPrurigo nodularis (PN) is a chronic inflammatory skin condition characterized by the presence of pruritic nodules. Dupilumab was approved by the US Food and Drug Administration in September 2022 and Health Canada in July 2023 for the treatment of PN. Dupilumab is a human monoclonal immunoglobulin G4 antibody that binds the interleukin (IL)-4 receptor alpha subunit, blocking intercellular signalling of IL-4 and IL-13. Inhibition of these cytokines downregulates the inflammatory response and improves disease severity and pruritus. Two randomized controlled trials have shown dupil...
Source: Skin Therapy Letter - November 28, 2023 Category: Dermatology Authors: Ayaa Alkhaleefa Taylor Evart Woo Laurie Parsons Source Type: research
Risankizumab in Adults with Psoriatic Arthritis
Skin Therapy Lett. 2023 Nov;28(6):1-6.ABSTRACTPsoriatic arthritis (PsA) is a chronic inflammatory musculoskeletal disease associated with psoriasis. Its major clinical domains include peripheral and axial arthritis, enthesitis, dactylitis and skin and nail involvement. Approximately 30% of patients with psoriasis develop psoriatic arthritis. The pathophysiology of PsA is complex and involves a dysregulated immune response. In particular, interleukin (IL)-23 is a major regulatory cytokine that has been implicated in PsA, including bone remodeling, enthesitis, synovitis and psoriatic lesions. Risankizumab is a humanized immu...
Source: Skin Therapy Letter - November 28, 2023 Category: Dermatology Authors: Karla Machlab Jensen Yeung Melinda Gooderham Source Type: research
Dupilumab for the Treatment of Prurigo Nodularis
Skin Therapy Lett. 2023 Nov;28(6):7-9.ABSTRACTPrurigo nodularis (PN) is a chronic inflammatory skin condition characterized by the presence of pruritic nodules. Dupilumab was approved by the US Food and Drug Administration in September 2022 and Health Canada in July 2023 for the treatment of PN. Dupilumab is a human monoclonal immunoglobulin G4 antibody that binds the interleukin (IL)-4 receptor alpha subunit, blocking intercellular signalling of IL-4 and IL-13. Inhibition of these cytokines downregulates the inflammatory response and improves disease severity and pruritus. Two randomized controlled trials have shown dupil...
Source: Skin Therapy Letter - November 28, 2023 Category: Dermatology Authors: Ayaa Alkhaleefa Taylor Evart Woo Laurie Parsons Source Type: research
Risankizumab in Adults with Psoriatic Arthritis
Skin Therapy Lett. 2023 Nov;28(6):1-6.ABSTRACTPsoriatic arthritis (PsA) is a chronic inflammatory musculoskeletal disease associated with psoriasis. Its major clinical domains include peripheral and axial arthritis, enthesitis, dactylitis and skin and nail involvement. Approximately 30% of patients with psoriasis develop psoriatic arthritis. The pathophysiology of PsA is complex and involves a dysregulated immune response. In particular, interleukin (IL)-23 is a major regulatory cytokine that has been implicated in PsA, including bone remodeling, enthesitis, synovitis and psoriatic lesions. Risankizumab is a humanized immu...
Source: Skin Therapy Letter - November 28, 2023 Category: Dermatology Authors: Karla Machlab Jensen Yeung Melinda Gooderham Source Type: research
Dupilumab for the Treatment of Prurigo Nodularis
Skin Therapy Lett. 2023 Nov;28(6):7-9.ABSTRACTPrurigo nodularis (PN) is a chronic inflammatory skin condition characterized by the presence of pruritic nodules. Dupilumab was approved by the US Food and Drug Administration in September 2022 and Health Canada in July 2023 for the treatment of PN. Dupilumab is a human monoclonal immunoglobulin G4 antibody that binds the interleukin (IL)-4 receptor alpha subunit, blocking intercellular signalling of IL-4 and IL-13. Inhibition of these cytokines downregulates the inflammatory response and improves disease severity and pruritus. Two randomized controlled trials have shown dupil...
Source: Skin Therapy Letter - November 28, 2023 Category: Dermatology Authors: Ayaa Alkhaleefa Taylor Evart Woo Laurie Parsons Source Type: research
Risankizumab in Adults with Psoriatic Arthritis
Skin Therapy Lett. 2023 Nov;28(6):1-6.ABSTRACTPsoriatic arthritis (PsA) is a chronic inflammatory musculoskeletal disease associated with psoriasis. Its major clinical domains include peripheral and axial arthritis, enthesitis, dactylitis and skin and nail involvement. Approximately 30% of patients with psoriasis develop psoriatic arthritis. The pathophysiology of PsA is complex and involves a dysregulated immune response. In particular, interleukin (IL)-23 is a major regulatory cytokine that has been implicated in PsA, including bone remodeling, enthesitis, synovitis and psoriatic lesions. Risankizumab is a humanized immu...
Source: Skin Therapy Letter - November 28, 2023 Category: Dermatology Authors: Karla Machlab Jensen Yeung Melinda Gooderham Source Type: research
Dupilumab for the Treatment of Prurigo Nodularis
Skin Therapy Lett. 2023 Nov;28(6):7-9.ABSTRACTPrurigo nodularis (PN) is a chronic inflammatory skin condition characterized by the presence of pruritic nodules. Dupilumab was approved by the US Food and Drug Administration in September 2022 and Health Canada in July 2023 for the treatment of PN. Dupilumab is a human monoclonal immunoglobulin G4 antibody that binds the interleukin (IL)-4 receptor alpha subunit, blocking intercellular signalling of IL-4 and IL-13. Inhibition of these cytokines downregulates the inflammatory response and improves disease severity and pruritus. Two randomized controlled trials have shown dupil...
Source: Skin Therapy Letter - November 28, 2023 Category: Dermatology Authors: Ayaa Alkhaleefa Taylor Evart Woo Laurie Parsons Source Type: research
Risankizumab in Adults with Psoriatic Arthritis
Skin Therapy Lett. 2023 Nov;28(6):1-6.ABSTRACTPsoriatic arthritis (PsA) is a chronic inflammatory musculoskeletal disease associated with psoriasis. Its major clinical domains include peripheral and axial arthritis, enthesitis, dactylitis and skin and nail involvement. Approximately 30% of patients with psoriasis develop psoriatic arthritis. The pathophysiology of PsA is complex and involves a dysregulated immune response. In particular, interleukin (IL)-23 is a major regulatory cytokine that has been implicated in PsA, including bone remodeling, enthesitis, synovitis and psoriatic lesions. Risankizumab is a humanized immu...
Source: Skin Therapy Letter - November 28, 2023 Category: Dermatology Authors: Karla Machlab Jensen Yeung Melinda Gooderham Source Type: research
Dupilumab for the Treatment of Prurigo Nodularis
Skin Therapy Lett. 2023 Nov;28(6):7-9.ABSTRACTPrurigo nodularis (PN) is a chronic inflammatory skin condition characterized by the presence of pruritic nodules. Dupilumab was approved by the US Food and Drug Administration in September 2022 and Health Canada in July 2023 for the treatment of PN. Dupilumab is a human monoclonal immunoglobulin G4 antibody that binds the interleukin (IL)-4 receptor alpha subunit, blocking intercellular signalling of IL-4 and IL-13. Inhibition of these cytokines downregulates the inflammatory response and improves disease severity and pruritus. Two randomized controlled trials have shown dupil...
Source: Skin Therapy Letter - November 28, 2023 Category: Dermatology Authors: Ayaa Alkhaleefa Taylor Evart Woo Laurie Parsons Source Type: research
Risankizumab in Adults with Psoriatic Arthritis
Skin Therapy Lett. 2023 Nov;28(6):1-6.ABSTRACTPsoriatic arthritis (PsA) is a chronic inflammatory musculoskeletal disease associated with psoriasis. Its major clinical domains include peripheral and axial arthritis, enthesitis, dactylitis and skin and nail involvement. Approximately 30% of patients with psoriasis develop psoriatic arthritis. The pathophysiology of PsA is complex and involves a dysregulated immune response. In particular, interleukin (IL)-23 is a major regulatory cytokine that has been implicated in PsA, including bone remodeling, enthesitis, synovitis and psoriatic lesions. Risankizumab is a humanized immu...
Source: Skin Therapy Letter - November 28, 2023 Category: Dermatology Authors: Karla Machlab Jensen Yeung Melinda Gooderham Source Type: research
Dupilumab for the Treatment of Prurigo Nodularis
Skin Therapy Lett. 2023 Nov;28(6):7-9.ABSTRACTPrurigo nodularis (PN) is a chronic inflammatory skin condition characterized by the presence of pruritic nodules. Dupilumab was approved by the US Food and Drug Administration in September 2022 and Health Canada in July 2023 for the treatment of PN. Dupilumab is a human monoclonal immunoglobulin G4 antibody that binds the interleukin (IL)-4 receptor alpha subunit, blocking intercellular signalling of IL-4 and IL-13. Inhibition of these cytokines downregulates the inflammatory response and improves disease severity and pruritus. Two randomized controlled trials have shown dupil...
Source: Skin Therapy Letter - November 28, 2023 Category: Dermatology Authors: Ayaa Alkhaleefa Taylor Evart Woo Laurie Parsons Source Type: research
